Haas Jason
Insider CIK 1883821 · SYRS Chief Financial Officer · ODTX Chief Financial Officer · LGND Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| LGND LIGAND PHARMACEUTICALS INC | M Exercise deriv | 2026-08-12 | 2026-08-14 | 6,138 | — | $0 | 0 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | S Sale | 2026-08-12 | 2026-08-14 | 7,138 | $292.81 | $2.09M | 3,981 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | M Exercise | 2026-08-12 | 2026-08-14 | 6,138 | $51.56 | $316.5K | 11,119 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | M Exercise deriv | 2026-08-12 | 2026-08-14 | 6,138 | — | $0 | 0 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | S Sale | 2026-08-12 | 2026-08-14 | 7,138 | $292.81 | $2.09M | 3,981 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | M Exercise | 2026-08-12 | 2026-08-14 | 6,138 | $51.56 | $316.5K | 11,119 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | M Exercise deriv | 2026-06-12 | 2026-06-15 | 1,000 | — | $0 | 6,138 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | M Exercise deriv | 2026-06-12 | 2026-06-15 | 3,000 | — | $0 | 7,138 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | M Exercise | 2026-06-12 | 2026-06-15 | 1,000 | $51.56 | $51.6K | 11,442 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | S Sale | 2026-06-12 | 2026-06-15 | 3,000 | $255.01 | $765.0K | 8,442 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | S Sale | 2026-06-12 | 2026-06-15 | 3,461 | $256.08 | $886.3K | 4,981 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | M Exercise | 2026-06-12 | 2026-06-15 | 3,000 | $51.56 | $154.7K | 10,442 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award deriv | 2026-06-05 | 2026-06-09 | 2,938 | — | $0 | 2,938 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award | 2026-06-05 | 2026-06-09 | 836 | — | $0 | 7,442 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | P Buy | 2026-05-08 | 2026-05-11 | 1,000 | $20.00 | $20.0K | 62,908 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award deriv | 2025-06-06 | 2025-06-10 | 5,783 | — | $0 | 5,783 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award | 2025-06-06 | 2025-06-10 | 1,209 | — | $0 | 6,606 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | S Sale | 2024-11-18 | 2024-11-20 | 137,803 | $0.21 | $28.9K | 0 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise deriv | 2024-10-31 | 2024-11-04 | 18,875 | — | $0 | 0 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise | 2024-10-31 | 2024-11-04 | 18,875 | — | $0 | 143,427 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | F Tax w/h | 2024-10-31 | 2024-11-04 | 5,624 | $2.09 | $11.8K | 137,803 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | P Buy | 2024-09-12 | 2024-09-12 | 45,344 | $1.68 | $76.2K | 124,552 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | P Buy | 2024-09-11 | 2024-09-12 | 19,293 | $1.58 | $30.5K | 79,208 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | P Buy | 2024-09-10 | 2024-09-12 | 35,363 | $1.55 | $54.8K | 59,915 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award deriv | 2024-06-14 | 2024-06-18 | 5,444 | — | $0 | 5,444 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award | 2024-06-14 | 2024-06-18 | 1,252 | — | $0 | 5,397 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | F Tax w/h | 2024-04-01 | 2024-04-02 | 4,732 | $5.12 | $24.2K | 24,552 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise deriv | 2024-03-31 | 2024-04-02 | 13,333 | — | $0 | 26,667 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise deriv | 2024-03-31 | 2024-04-02 | 2,000 | — | $0 | 4,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise | 2024-03-31 | 2024-04-02 | 2,000 | — | $0 | 15,951 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise | 2024-03-31 | 2024-04-02 | 13,333 | — | $0 | 29,284 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | F Tax w/h | 2023-11-01 | 2023-11-02 | 6,301 | $2.22 | $14.0K | 13,951 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise deriv | 2023-10-31 | 2023-11-02 | 18,875 | — | $0 | 18,875 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise | 2023-10-31 | 2023-11-02 | 18,875 | — | $0 | 20,252 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award deriv | 2023-06-09 | 2023-06-13 | 5,461 | — | $0 | 5,461 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award | 2023-06-09 | 2023-06-13 | 1,142 | — | $0 | 4,145 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | F Tax w/h | 2023-04-03 | 2023-04-04 | 623 | $2.58 | $1.6K | 1,377 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise deriv | 2023-03-31 | 2023-04-04 | 2,000 | — | $0 | 6,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | M Exercise | 2023-03-31 | 2023-04-04 | 2,000 | — | $0 | 2,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2023-02-16 | 2023-02-21 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2022-10-06 | 2022-10-11 | 37,750 | — | $0 | 37,750 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2022-10-06 | 2022-10-11 | 49,750 | — | $0 | 49,750 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award deriv | 2022-06-29 | 2022-06-30 | 5,907 | — | $0 | 5,907 | SEC↗ |
| LGND LIGAND PHARMACEUTICALS INC | A Award | 2022-06-29 | 2022-06-30 | 1,750 | — | $0 | 1,750 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2022-02-15 | 2022-02-17 | 80,000 | — | $0 | 80,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2022-02-15 | 2022-02-17 | 125,000 | — | $0 | 125,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2021-10-12 | 2021-10-13 | 750,000 | — | $0 | 750,000 | SEC↗ |